7月1日 - ** 生物制药公司BioXcel Therapeutics BTAI.O股价盘前上涨11.6%至2.02美元
** BTAI表示，它已收到独立数据安全监测委员会的第二份积极建议，继续进行其实验性药物的后期研究，以治疗双相情感障碍I型或II型患者或精神分裂症患者的躁动。
** BTAI正在对200名患者进行BXCL501的测试，以治疗与阿尔茨海默氏症痴呆和I、II型双相情感障碍或精神分裂症相关的家庭环境中的躁动。
** 公司预计将于 2025 年第三季度获得后期研究数据
** 截至上一交易日收盘，股价累计下跌 69.7
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.